252 related articles for article (PubMed ID: 27756888)
1. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
[TBL] [Abstract][Full Text] [Related]
2. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
[TBL] [Abstract][Full Text] [Related]
3. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
7. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
9. MSH2 Loss in Primary Prostate Cancer.
Guedes LB; Antonarakis ES; Schweizer MT; Mirkheshti N; Almutairi F; Park JC; Glavaris S; Hicks J; Eisenberger MA; De Marzo AM; Epstein JI; Isaacs WB; Eshleman JR; Pritchard CC; Lotan TL
Clin Cancer Res; 2017 Nov; 23(22):6863-6874. PubMed ID: 28790115
[No Abstract] [Full Text] [Related]
10. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.
Kaur HB; Salles DC; Paulk A; Epstein JI; Eshleman JR; Lotan TL
Histopathology; 2021 Jan; 78(2):327-333. PubMed ID: 32740981
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function.
Klarskov L; Holck S; Bernstein I; Okkels H; Rambech E; Baldetorp B; Nilbert M
Am J Surg Pathol; 2011 Sep; 35(9):1391-9. PubMed ID: 21836479
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
13. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
[TBL] [Abstract][Full Text] [Related]
14. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
15. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Katz MHG; Wang H; Cuddy A; You YN
JAMA Surg; 2017 Nov; 152(11):1086-1088. PubMed ID: 28793134
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
[TBL] [Abstract][Full Text] [Related]
19. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
[TBL] [Abstract][Full Text] [Related]
20. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]